Monte Rosa Therapeutics, Inc.
GLUENext catalyst
Oral MRT-2359
NSCLC
Get an email about GLUE's next catalysts
Track Monte Rosa Therapeutics (GLUE) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
No other upcoming event in our data.
1 upcoming, 1 past
Oral MRT-2359 Phase 2 Est. Readout (MODeFIRe-1)
Estimated primary completion for Oral MRT-2359 trial (NCT07745361) in Castration-Resistant Prostate Cancer (CRPC). Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Oral MRT-2359 | Phase 2 | NSCLC | - | - |
Apalutamide | Phase 2 | Castration-Resistant Prostate Cancer (CRPC) | - | - |
Frequently asked questions
What is in Monte Rosa Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Monte Rosa Therapeutics, Inc.'s (GLUE) pipeline across Phase 2. Its lead program is Oral MRT-2359 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Monte Rosa Therapeutics, Inc.'s next FDA catalyst?→
Monte Rosa Therapeutics, Inc.'s (GLUE) next tracked catalyst is a Phase 2 readout expected October 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track GLUE biotech catalysts?→
Add GLUE to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Monte Rosa Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.